MedAssets (MDAS) (HUM) (SNCR) (DLR) (FRO) (ARIA) (ALGT) (CPLP) (GEVO) Price Targets Changed

MedAssets, Inc. (NASDAQ: MDAS), Humana (NYSE: HUM), Synchronoss Technologies, Inc. (NASDAQ: SNCR), Digital Realty Trust, Inc. (NYSE: DLR), Frontline Ltd. (NYSE: FRO), Ariad Pharmaceutical (NASDAQ: ARIA), Allegiant Travel (NASDAQ: ALGT), Capital Product Partners L.P. (NASDAQ: CPLP) and Gevo, Inc. (NASDAQ: GEVO) price targets adjusted by analysts.

MedAssets, Inc. (MDAS) had its price target lowered by UBS AG (NYSE:UBS) from $15.50 to $13.00. The have a “Neutral” rating on the company.

Humana (NYSE: HUM) had its price target raised by Barclays Capital from $85.00 to $90.00. They have an “Equal Weight” rating on the company.

Synchronoss Technologies, Inc. (SNCR) had its price target raised by Stifel Nicolaus from $38.00 to $44.00. They have a “Buy” rating on the company.

Digital Realty Trust, Inc. (DLR) had its price target lowered by Barclays Capital from $70.00 to $67.00. They have an “Overweight” rating on the company.

Frontline Ltd. (FRO) had its price target lowered by Deutsche Bank (NYSE:DB) from $22.00 to $16.00. They have a “Buy” rating on the company.

Ariad Pharmaceutical (ARIA) had its price target raised by Brean Murray from $11.00 to $15.00. They have a “Buy” rating on the company.

Allegiant Travel (ALGT) had its price target cut by Barclays Capital from $65.00 to $61.00. They have an “Overweight” rating on the company.

Capital Product Partners L.P. (CPLP) had its price target lowered by Deutsche Bank from $9.00 to $8.00. They have a “Hold” rating on the company.

Gevo, Inc. (GEVO) had its price target boosted by UBS AG from $21.00 to $23.00. They have a “Buy” rating on the company.

Ratings on (GEVO) (HANS) (MYGN) (NIHD) (NTES) Reiterated

Ratings on shares of Gevo, Inc. (NASDAQ: GEVO), Hansen Natural Co. (NASDAQ: HANS), Myriad Genetics (NASDAQ: MYGN), NII Holdings (NASDAQ: NIHD) and NetScout Systems, Inc. (NASDAQ: NTCT) were reiterated by analysts.

Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Gevo, Inc. (GEVO). They have a price target of $31.00 on the company.

Gabelli reiterated a “buy” rating on Hansen Natural Co. (HANS).

Morgan Stanley (NYSE:MS) reiterated an “equal weight” rating on Myriad Genetics (MYGN).

Gabelli reiterated a “buy” rating on NII Holdings (NIHD).

Bank of America (NYSE:BAC) reiterated a “buy” rating on Netease.com Inc (NTES).